JMP keeps Human Genome at market outperform

Human Genome Sciences, Inc. was reiterated by JMP Securities analyst Charles C. Duncan at market outperform with a $15 price target. The company's Albuferon shows continued emerging efficacy in treatment-failure hepatitis C virus (HCV) patients. Human Genome presented interim data from its phase 2 Albuferon trial in interferon-experienced HCV patients. JMP anticipates a phase 3 study to begin by the end of the year in treatment-naïve HCV patients but believes based on the positive interim analysis that Albuferon could have two routes to market and a larger commercial opportunity in the interferon-failure HCV population. Shares of the Rockville, Md., biopharmaceutical company were down 3 cents, or 0.27%, at $10.96 on volume of 2,206,071 shares versus the three-month running average of 3,689,320 shares. (Nasdaq: HGSI)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.